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Abstract  21 
Forty-one cattle from seven Belgian farms and two French farms confirmed as infected with 22 
bluetongue virus serotype 8 (BTV-8) were monitored from the onset of clinical signs in order 23 
to describe the disease pattern and estimate the duration of blood RT-qPCR and cELISA 24 
positivity under field conditions. On each visit, blood samples were taken and a standardised 25 
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clinical form filled in for each animal. A clinical score was calculated for every week until the 26 
end of clinical signs. A classification and regression tree (CART) analysis was conducted to 27 
determine the most important clinical signs every week for the first seven weeks. The highest 28 
scores were recorded within two weeks of clinical onset. The first recorded clinical signs were 29 
quite obviously visible (tiredness and limited walking, conjunctivitis, lesions of nasal mucosa, 30 
nasal discharge). Skin lesions, a drop in milk production and weight loss appeared later in the 31 
course of the disease. A biphasic pattern regarding nasal lesions was noticed: the first peak 32 
concerned mainly congestive and ulcerative lesions, whereas the second peak mainly 33 
concerned crusty lesions. The median time estimated by survival analysis to obtain negative 34 
RT-qPCR results from the onset of clinical signs was 195 days (range 166 to 213 days) in the 35 
23 cattle included in the analysis. Serological results remained strongly positive until the end 36 
of the study. These results should ensure more accurate detection of an emerging infectious 37 
disease and are of prime importance in improving the modelling of BTV-8 persistence in 38 
Europe. 39 
 40 
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1. Introduction 43 
Bluetongue (BT) is a vector-borne viral disease of wild and domestic ruminants caused by a 44 
double-stranded RNA virus of the family Reoviridae, genus Orbivirus (Roy, 1992). The BT 45 
virus (BTV) consists of 26 serotypes (Maan et al., 2011), principally transmitted by several 46 
species of biting midges of the family Ceratopogonidae, genus Culicoides (Mellor and 47 
Wittmann, 2002). Since 1998, five distinct serotypes of BTV (1, 2, 4, 9 and 16) have spread 48 
across Southern and Central Europe (Mellor and Wittmann, 2002; Schwartz-Cornil et al., 49 
2008). In August 2006, a sixth serotype—BTV-8—was first identified in Northern Europe, 50 
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from where it quickly spread throughout the Netherlands, Belgium, Luxembourg, Germany 51 
and Northern France (Darpel et al., 2007; Durand et al., 2010; Elbers et al., 2008b; Saegerman 52 
et al., 2008a; Saegerman et al., 2010; Toussaint et al., 2006). By the end of 2009, BTV-8 had 53 
spread to most countries in Western and Central Europe, including Austria, the Czech 54 
Republic, Denmark, Hungary, Italy, Luxembourg, Norway, Spain, Sweden and the United 55 
Kingdom. 56 
Clinical signs of BTV are tipically associated with sheep, as cattle generally remain 57 
asymptomatic (Guyot et al., 2007). The BTV-8 incursion in Europe caused cattle to show 58 
clinical signs that had never been reported previously (Landeg, 2007; Thiry et al., 2006). The 59 
clinical signs observed in this species in Europe have been described, but the corresponding 60 
stage of the disease was not specified as the information was very likely collected during 61 
occasional veterinarian inspections or reported by farmers (Elbers et al., 2008a; Elbers et al., 62 
2009; Landeg, 2007; Le Gal et al., 2008; Thiry et al., 2006). Only experimental studies with a 63 
small sample of calves (Dal Pozzo et al., 2009; Darpel et al., 2007; Martinelle et al., 2011) 64 
have attempted to describe the course of the disease caused by BTV-8. On the other hand, 65 
cattle have been reported to remain positive to BTV by RT-qPCR for a long period of time 66 
(MacLachlan, 2004). This period has occasionally been estimated in field conditions (Katz et 67 
al., 1994) but more usually following experimental inoculations (Barratt-Boyes and 68 
MacLachlan, 1995). For BTV-8, no reliable field data are available (EFSA Panel on Animal 69 
Health and Welfare (AHAW), 2011).   70 
We herein describe the results of a joint French-Belgian study to characterise the clinical 71 
course taken by BTV-8 infected cattle under field conditions. Blood samples were taken 72 
regularly to estimate the duration of blood RT-qPCR and cELISA positivity in cattle naturally 73 




2. Materials and methods 76 
2.1. Animals 77 
Animals included in the study were selected from zones where several BTV-8 outbreaks were 78 
confirmed in the 2006 summer for Belgium and in the 2008 summer for France. All the 79 
animals displaying BTV clinical signs for the first time (Guyot et al., 2008) on one farm and 80 
confirmed as BTV cases by RT-qPCR and cELISA were included in the study. In Belgium, 81 
the study was conducted on seven farms in the province of Liège, the most likely place of 82 
introduction of BTV-8 into Belgian ruminants (Saegerman et al., 2010). Twenty-one adult 83 
cattle (2.5 to 15 years old) of three different breeds (17 Holstein, 3 Red Pied Westphalian and 84 
1 Limousine) were included. Eighteen were followed from August 2006 to October 2006 and 85 
three from August 2006 to April 2007.  86 
Twenty adult cattle of Holstein, Normand and Simmental breeds were selected from two 87 
distinct farms located in the North of France. The clinical follow-up of the animals was 88 
conducted between August 2008 and July 2009.  89 
There had been no records or bovine viral diarrhea or infectious bovine rhinotracheitis 90 
occurrence in the selected farms. Farmers also declared that it was the first time they had 91 
observed that set of clinical signs in their animals. Therefore, considering the epidemiological 92 
context, it was unlikely that the observed clinical signs have been caused by other etiologies.  93 
2.2. Follow-up of clinical signs and sampling 94 
In Belgium, a standardised clinical form  (Saegerman et al., 2008b) was filled in by three 95 
veterinarians on days 0 (clinical onset as noticed by the farmers), 7, 15, 21, 29 and 52. Blood 96 
samples were taken from three of these cattle on day 0 and then every 15 days in the first 97 
month and once every month until the first negative RT-qPCR result.  98 
In France, two veterinarians were in charge of the clinical inspections and samplings on the 99 
two selected farms throughout the study. The same clinical standardised form used in 100 
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Belgium was filled in on each veterinarian visit. For some animals, the first visit occurred a 101 
few days after clinical onset and the date of appearance of clinical signs was reported by the 102 
farmer. For other animals, the first visit corresponded to the appearance of clinical signs. 103 
Afterwards, the selected animals were clinically inspected and blood samples were taken 104 
every week in the first month, every two weeks in the second and third months and then once 105 
every month. A year elapsed between the first visit and the last visit.  106 
BTV clinical signs were classified into 19 categories (Table 1). The clinical score represents 107 
the sum of an animal’s clinical signs. It was recorded every week from day 0 until the end of 108 
clinical signs for the 41 animals included in the study. 109 
All blood samples were tested by RT-qPCR and cELISA.   110 
 111 
2.3. Laboratory assays 112 
The laboratory assays were conducted at the Laboratoire Nationale de Contrôle des 113 
Reproducteurs, Maisons-Alfort, France; the Department of Infectious and Parasitic Diseases, 114 
Faculty of Veterinary Medicine, University of Liège and the Veterinary and Agrochemical 115 
Research Centre, Liège, Belgium. 116 
 117 
2.3.1. BTV RT-qPCR  118 
All the samples were evaluated with a pan-BTV RT-qPCR (Toussaint et al., 2007) targeting a 119 
segment 1 sequence, well conserved among BTV serotypes (BTV M ®, LSI, Lissieu, France). 120 
This RT-qPCR includes an internal control (a housekeeping RNA specific sequence). Briefly, 121 
5 µL of RNA were denatured (3 minutes at 95°C) and incubated with 20 µL of the RT-qPCR 122 
mix in a thermocycler (ABIPRISM ® - APPLIED Biosystems). After reverse transcription 123 
(10 minutes at 45°C), a 40-cycle amplification was performed as follows: 1 cycle of 10 124 
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minutes at 95°C then 40 Cycles: 15 sec. at 95°C + 60 sec. at 60 °C. A result was considered 125 
positive when the cycle threshold [Ct] value < 40.  126 
 127 
2.3.2. cELISA 128 
BTV antibody levels were measured using the cELISA ‘ID Screen® Bluetongue Competition’ 129 
assay (ID VET, Montpellier, France) according to the manufacturer’s instructions. Results 130 
were expressed as % of negativity (PN) compared to the kit control and considered a positive, 131 
doubtful or negative result according to the cut-off settings provided by the manufacturer (PN 132 
≤ 35 is positive; 35 < PN ≤ 45 is doubtful; PN > 45 is negative). 133 
 134 
2.4. Statistical analyses 135 
2.4.1. Classification and regression tree (CART) analysis 136 
A CART analysis was conducted on the dataset for the first seven weeks (until the upper limit 137 
of the mean clinical score +/- standard deviation was below 1; see Figure 1) of the period 138 
observed, where the presence or absence of clinical signs during each week was used as the 139 
dependent variable and clinical signs were used as independent or predictor variables. Briefly, 140 
a CART analysis is a non-linear, non-parametric model that is fitted by binary recursive 141 
partitioning of multidimensional covariate space. Using CART 6.0 software (Salford Systems, 142 
San Diego, CA, USA), the analysis successively splits the dataset into increasingly 143 
homogeneous subsets until it is stratified to meet specified criteria. The Gini index was used 144 
as the splitting method, and a 10-fold cross-validation was used to test the predictive capacity 145 
of the obtained trees. For each node in a CART-generated tree, the “primary splitter” is the 146 
variable that best splits the node, maximizing the purity of the resulting nodes. Further details 147 
on CART are given in previously published articles (Breiman et al., 1984; Saegerman et al., 148 




2.4.2. Survival analysis 151 
All the 20 French cattle and three Belgian cattle — for which follow-up RT-qPCR results 152 
were available — were included in a survival analysis, used to estimate how long it takes for 153 
an event to occur. In this study, the event was the animal becoming negative to RT-qPCR. 154 
The duration of RT-qPCR positive blood results after the occurrence of the first clinical signs 155 
was determined using the non-parametric survival Kaplan-Meier method.  156 
Statistical analysis and graphs were performed with R (R development Core Team, 2009). 157 
 158 
3. Results 159 
3.1. Follow-up of clinical signs 160 
The highest scores in the 41 cattle (total of 415 observations) were recorded in the first two 161 
weeks after clinical onset (Figure 1). They gradually decreased until the 10
th
 week, after 162 
which most of the animals showed no more clinical signs.  163 
 164 
3.2. CART analysis 165 
To investigate the relative importance of clinical signs depending on the duration of the 166 
disease, a CART analysis was performed for the first seven weeks and the variable 167 
importance of clinical signs recorded for each week (Table 1). The most important clinical 168 
signs recorded first were conjunctivitis, lacrimation and peri-ocular dermatitis (variable 169 
importance of 100), tiredness, limited walking (variable importance of 92) and ulcerative 170 
lesions of nasal mucosa (variable importance of 32) and mucous, serous, aqueous nasal 171 
discharge (variable importance of 26). Ulcerative lesions of nasal mucosa were the most 172 
important clinical signs in the second and in the third week with addition of anorexia or loss 173 
of appetite. They remained important in the fourth week (variable importance of 91) and were 174 
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not prominent during the fifth and sixth week. In the seventh week lesions of nasal mucosa 175 
were recorded again as an important clinical sign (variable importance of 76) but lesions were 176 
mainly crusts instead of ulcerations. In the seventh week, the most important clinical sign was 177 
milk loss (variable importance of 100) followed by ulcerative lesions of nasal mucosa 178 
(variable importance of 76). 179 
 180 
3.3. RT-qPCR and cELISA results 181 
The Ct values for 23 animals for which RT-qPCR results were available are summarised in 182 
Figure 2. The lowest Ct value obtained was 20 within the first week of the onset of clinical 183 
signs. Between 24 and 31 weeks, all the animals had a Ct≥41 (see following paragraph). 184 
 185 
All the samples collected gave positive results in cELISA from the day of first sampling until 186 
the last date of sampling. For the 20 French cattle, PN values never exceeded 14% and the last 187 
blood samples were taken between 300 and 349 days after the appearance of clinical signs. 188 
For the three Belgian cattle, the last blood samples were taken on days 177, 177 and 213 189 
respectively, and their PN values were below 10%.   190 
 191 
3.4. Estimated time to RT-qPCR negative status using survival analysis 192 
The Kaplan Meier survival curve shows that the time taken to obtain negative BTV-8 RT-193 
qPCR results following the onset of clinical signs ranges from 166 to 213 days in the 23 cattle 194 
included in the survival analysis (Figure 3). The median time was of 195 days. 195 
 196 
4. Discussion 197 
A distinction must be made between clinical signs as they objectively occur during the course 198 
of a disease, and clinical signs that will lead to a veterinary call-out. Some moderate clinical 199 
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signs can easily remain unnoticed or are not severe enough to justify medication and are thus 200 
not recorded. This is the case for BTV-8 disease in cattle, which is considered a mild 201 
affection. A critical point is the observation pressure, which is directly related to the 202 
epidemiological context (a breeder will be more aware of an expected disease) and the 203 
potential economic losses, i.e. many diseases become apparent when animals are affected 204 
enough to significantly lower the breeder’s income. Keeping these aspects in mind, it is likely 205 
that reported clinical signs of BTV-8 in cattle in the field up to now correspond to signs 206 
observed at stages of the disease when they were already prominent. Only a follow-up of 207 
cattle from the first detectable signs in the field could allow the course of the disease to be 208 
accurately described.  209 
In our study, the first recorded clinical signs were quite obviously visible (conjunctivitis, 210 
lesions of nasal mucosa, nasal discharge). In comparison, in experimental infections the first 211 
clinical signs are usually oral inflammation of different grades, often unrelated to appetite loss 212 
(Dal Pozzo et al., 2009; Martinelle et al., 2011). A slight oral congestion would obviously 213 
remain unnoticed in the field whereas a thoroughly standardised clinical examination would 214 
clearly detect it, particularly since examinations in an experimental context would start before 215 
the very first signs had even occurred. It is interesting to note that in some experimental 216 
infections, when the clinical picture is mild, conjunctivitis may be the earliest recorded 217 
clinical sign (Martinelle et al., 2011). This could support the general mildness of the clinical 218 
cases encountered in the field. During the second week of clinical manifestations, ulcerative 219 
lesions of the nasal mucosa took over from ocular lesions. This confirms conjunctivitis as an 220 
acute lesion, whereas muzzle ulcerations tend to be chronic. No other clear clinical sign 221 
seemed to be reported during the second week. In the third week, nasal lesions remained in 222 
first place, but were then associated with anorexia or loss of appetite and ulcerative lesions of 223 
oral mucosa and excoriation. The latter is more likely a cause of anorexia or loss of appetite, 224 
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as oral inflammation is considered a early, long-lasting lesion in an experimental context, 225 
possibly leading to a lack of appetite and subsequently an examination of the oral cavity. In 226 
the fourth week, nasal lesions were preeminent, and weight loss noted as a consequence of 227 
loss of appetite. Weight loss took the lead during the fifth week. Milk loss probably started 228 
sooner, during the acute phase of the disease, but this loss can remain unnoticed several weeks 229 
before becoming clearly significant. Skin lesions of the udder, teat or vulva are also described 230 
as late lesions. Six weeks after the start of clinical manifestations, ocular lesions were again 231 
the most reported clinical entity. This could be related to the inclusion of “peri-ocular 232 
dermatitis”, which could also be regarded as a photosensitivity-like related lesion, already 233 
described as a late lesion, as opposed to conjunctivitis, which is clearly more acute. Milk loss 234 
was increasing, and swelling of the coronary band was also an important clinical sign. In the 235 
seventh week, milk loss asserted itself as the most frequently-reported clinical sign, followed 236 
by nasal lesions. A biphasic pattern regarding nasal lesions has already been reported in an 237 
experimental context (Martinelle et al., 2011), but with a shorter gap between the two peaks 238 
of nasal lesion manifestations. In our study, the first peak was more about congestive and 239 
ulcerative lesions, whereas the second week mainly concerned crusty lesions. Weight loss was 240 
still important during late weeks. 241 
BTV nucleic acid may be detected by RT-PCR in the blood of infected cattle and sheep when 242 
the infectious virus can no longer be detected by virus isolation in cell culture or inoculation 243 
of susceptible sheep (Maclachlan et al., 2009; MacLachlan et al., 1994). BTV-8 RNA was 244 
detected by real time RT-PCR in the blood of calves up to 151-157 days post infection after 245 
experimental inoculation (Di Gialleonardo et al., 2011). In the current study, BTV-8 RNA 246 
was detected by real time RT-PCR up to 166 - 213 days after the onset of clinical signs, which 247 
is longer than described in the above experimental study.  The persistence of BTV nucleic 248 
acid in the blood of infected ruminants has been linked to the normal lifespan of erythrocytes 249 
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(Barratt-Boyes and MacLachlan, 1995): in vitro virus particles persisted in invaginations of 250 
erythrocyte membranes (Brewer and MacLachlan, 1994). Erythrocytes are long-lasting cells 251 
and estimates of their normal circulatory lifespan range from 130 to 160 days in sheep and 252 
slightly longer in cattle (Katz et al., 1994). Long-term experimental studies conducted in 253 
sheep showed that BTV RNA was  detected by real-time RT-PCR up to 133 days post-254 
infection (three sheep inoculated with BTV-8) (Worwa et al., 2010). However, in another 255 
study, genome was continuously detected by RT-PCR in three sheep up to 111 - 222 days 256 
after infection with BTV-17 (Bonneau et al., 2002). It seems, therefore, that the range of BTV 257 
detection time by RT-PCR is similar in sheep and cattle. This observation should, however, be 258 
confirmed by future longitudinal studies including a larger population of naturally-infected 259 
sheep.  260 
 261 
In conclusion, this longitudinal study gives important information concerning the clinical 262 
characterisation of cattle naturally infected with BTV-8 and their evolution over time. The 263 
collaboration between countries, the standardisation of clinical signs and the use of more 264 
advanced tools (e.g. classification and regression tree) could be the way to further collate 265 
information Europe-wide and ensure more accurate detection of emerging infectious diseases. 266 
Repeated sampling allowed us to estimate the duration of blood BTV-8 RT-qPCR positivity. 267 
The estimation of this duration is of prime importance for improving the modelling of BTV-8 268 
persistence in Europe. Furthermore, the low PN cELISA values found in the naturally-269 
infected animals included in the current study over a whole year suggest that these animals 270 
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Table 1. Variable importance in CART analysis during the first seven weeks 398 
 399 
Figure 1. Mean clinical score observed by week after the first clinical appearance (+/- SD) 400 
X-axis: week(s) after the first clinical appearance; number of animals involved each period of 401 
time in brackets (during weeks 10 to 50, animals were observed several times). Y-axis: mean 402 
clinical score +/- standard deviation 403 
 404 
Figure 2. RT-qPCR Ct value box plots for 23 cattle by week after the first clinical appearance 405 
(a line indicates the median value, a box the inter-quartile range and bars the range) 406 
 407 
Figure 3. Kaplan-Meier survival curve for time to obtain negative BTV-8 RT-qPCR results in 408 























Conjunctivitis, lacrimation, peri-ocular 





 Ulcerative lesions of nasal mucosa, 
crusts 32 100 98 91 
  
76 
Mucous, serous, aqueous nasal 












Congestion, erythema, redness of 
buccal mucosa and/or muzzle 
 
21 7 19 
 
61 









 Swelling of the head, tongue, sub-





 Udder/Vulva Skin lesions of udder, teat or vulva 1 
  
9 32 18 
 Limbs Swelling of coronary bands 
 
7 
   
62 3 
General 
Lameness or generalised stiffness 




Anorexia or Loss of appetite 
  
100 18 6 39 32 
 


















 Weight loss 
   
62 100 5 41 
Muscular atrophia 
   
36 
   Anoestrus 





   





Figure 1. Mean clinical score observed by week after the first clinical appearance (+/- SD) 414 
X-axis: week(s) after the first clinical appearance; lower limit of the interval; number of 415 
animals involved each period of time in brackets (during weeks 10 to 50, animals were 416 





Figure 2. RT-PCR Ct value box plots for 23 cattle by week after the first clinical appearance 420 





Figure 3. Kaplan-Meier survival curve for time to obtain negative BTV-8 RT-PCR results in 424 
23 cattle 425 
0 50 100 150 200
0
.0
0
.2
0
.4
0
.6
0
.8
1
.0
PCR duration (days)
s
u
rv
iv
a
l 
p
ro
b
a
b
il
it
y
 426 
 427 
